Clinical implications of VUS reclassification in a single-centre series from application of ACMG/AMP classification rules specified forBRCA1/2

医学遗传学 基因检测 遗传咨询 一致性(知识库) 医学 计算机科学 生物信息学 遗传学 内科学 生物 人工智能 基因
作者
Giovanni Innella,Simona Ferrari,Sara Miccoli,Elena Luppi,Cristina Fortuño,Michael T. Parsons,Amanda B. Spurdle,Daniela Turchetti
出处
期刊:Journal of Medical Genetics [BMJ]
卷期号:: jmg-109694 被引量:1
标识
DOI:10.1136/jmg-2023-109694
摘要

Background BRCA1/2 testing is crucial to guide clinical decisions in patients with hereditary breast/ovarian cancer, but detection of variants of uncertain significance (VUSs) prevents proper management of carriers. The ENIGMA (Evidence-based Network for the Interpretation of Germline Mutant Alleles) BRCA1/2 Variant Curation Expert Panel (VCEP) has recently developed BRCA1/2 variant classification guidelines consistent with ClinGen processes, specified against the ACMG/AMP (American College of Medical Genetics and Genomics/Association for Molecular-Pathology) classification framework. Methods The ClinGen-approved BRCA1/2- specified ACMG/AMP classification guidelines were applied to BRCA1/2 VUSs identified from 2011 to 2022 in a series of patients, retrieving information from the VCEP documentation, public databases, literature and ENIGMA unpublished data. Then, we critically re-evaluated carrier families based on new results and checked consistency of updated classification with main sources for clinical interpretation of BRCA1/2 variants. Results Among 166 VUSs detected in 231 index cases, 135 (81.3%) found in 197 index cases were classified by applying BRCA1/2- specified ACMG/AMP criteria: 128 (94.8%) as Benign/Likely Benign and 7 (5.2%) as Pathogenic/Likely Pathogenic. The average time from the first report as ‘VUS’ to classification using this approach was 49.4 months. Considering that 15 of these variants found in 64 families had already been internally reclassified prior to this work, this study provided 121 new reclassifications among the 151 (80.1%) remaining VUSs, relevant to 133/167 (79.6%) families. Conclusions These results demonstrated the effectiveness of new BRCA1/2 ACMG/AMP classification guidelines for VUS classification within a clinical cohort, and their important clinical impact. Furthermore, they suggested a cadence of no more than 3 years for regular review of VUSs, which however requires time, expertise and resources.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
顺心火龙果完成签到,获得积分10
1秒前
murpuy完成签到,获得积分10
1秒前
狂野忆文发布了新的文献求助10
2秒前
狂野忆文发布了新的文献求助10
2秒前
在水一方应助qq采纳,获得10
2秒前
狂野忆文发布了新的文献求助10
2秒前
小青龙发布了新的文献求助10
3秒前
司徒文青应助Lucas采纳,获得30
3秒前
4秒前
wei完成签到,获得积分20
6秒前
6秒前
阿Q完成签到,获得积分10
7秒前
7秒前
8秒前
宇宙第一帅发布了新的文献求助200
9秒前
羊肉泡馍发布了新的文献求助10
9秒前
徐小赞发布了新的文献求助10
10秒前
结实大白完成签到,获得积分10
11秒前
PRIPRO关注了科研通微信公众号
11秒前
魔幻的觅珍完成签到,获得积分10
11秒前
文献达人完成签到,获得积分10
11秒前
11秒前
11秒前
共享精神应助欢喜的心情采纳,获得10
11秒前
冰千蕙发布了新的文献求助10
12秒前
MZ发布了新的文献求助10
13秒前
时尚战斗机应助善良的人采纳,获得10
13秒前
14秒前
领导范儿应助满anna采纳,获得10
14秒前
秦玉蓉发布了新的文献求助10
15秒前
16秒前
必中完成签到,获得积分20
17秒前
英姑应助wang采纳,获得10
18秒前
所所应助ylver采纳,获得50
18秒前
reirei应助sun_lin采纳,获得10
19秒前
眼睛大雨筠应助云ch采纳,获得60
20秒前
热心市民小红花应助Cici采纳,获得10
22秒前
秦玉蓉完成签到,获得积分10
22秒前
传奇3应助微微采纳,获得10
23秒前
23秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Cognitive Neuroscience: The Biology of the Mind 1000
Technical Brochure TB 814: LPIT applications in HV gas insulated switchgear 1000
Toward a Combinatorial Approach for the Prediction of IgG Half-Life and Clearance 500
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Picture Books with Same-sex Parented Families: Unintentional Censorship 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3969940
求助须知:如何正确求助?哪些是违规求助? 3514642
关于积分的说明 11175298
捐赠科研通 3249947
什么是DOI,文献DOI怎么找? 1795178
邀请新用户注册赠送积分活动 875617
科研通“疑难数据库(出版商)”最低求助积分说明 804891